Glycosyltransferase

Most glycosyltransferase enzymes form one of two folds: GT-A or GT-B

Glycosyltransferases (abbre. GTFs, Gtfs) are enzymes (EC 2.4) that establish natural glycosidic linkages. They catalyze the transfer of saccharide moieties from an activated nucleotide sugar (also known as the "glycosyl donor") to a nucleophilic glycosyl acceptor molecule, the nucleophile of which can be oxygen- carbon-, nitrogen-, or sulfur-based.[1]

The result of glycosyl transfer can be a carbohydrate, glycoside, oligosaccharide, or a polysaccharide. Some glycosyltransferases catalyse transfer to inorganic phosphate or water. Glycosyl transfer can also occur to protein residues, usually to tyrosine, serine, or threonine to give O-linked glycoproteins, or to asparagine to give N-linked glycoproteins. Mannosyl groups may be transferred to tryptophan to generate C-mannosyl tryptophan, which is relatively abundant in eukaryotes. Transferases may also use lipids as an acceptor, forming glycolipids, and even use lipid-linked sugar phosphate donors, such as dolichol phosphates.

Glycosyltransferases that use sugar nucleotide donors are Leloir enzymes, after Luis F. Leloir, the scientist who discovered the first sugar nucleotide and who received the 1970 Nobel Prize in Chemistry for his work on carbohydrate metabolism. Glycosyltransferases that utilize non-nucleotide donors such as dolichol or polyprenol pyrophosphate are non-Leloir glycosyltransferases.

Mammals utilize only 9 sugar nucleotide donors for glycosyltransferases:[2] UDP-glucose, UDP-galactose, UDP-GlcNAc, UDP-GalNAc, UDP-xylose, UDP-glucuronic acid, GDP-mannose, GDP-fucose, and CMP-sialic acid. The phosphate(s) of these donor molecules are usually coordinated by divalent cations such as manganese, however metal independent enzymes exist.

Mechanism

Glycosyltransferases can be segregated into “retaining” or“ inverting” enzymes according to whether the stereochemistry of the donor’s anomeric bond is retained (α→α) or inverted (α→β) during the transfer. The inverting mechanism is straightforward, requiring a single nucleophilic attack from the accepting atom to invert stereochemistry.

The retaining mechanism has been a matter of debate, but there exists strong evidence against a double displacement mechanism (which would cause two inversions about the anomeric carbon for a net retention of stereochemistry) or a dissociative mechanism (a prevalent variant of which was known as SNi). An “orthogonal associative” mechanism has been proposed which, akin to the inverting enzymes, requires only a single nucleophilic attack from an acceptor from a non-linear angle (as observed in many crystal structures) to achieve anomer retention.[3]

Reaction Reversibility

The recent discovery of the reversibility of many reactions catalyzed by inverting glycosyltransferases served as a paradigm shift in the field and raises questions regarding the designation of sugar nucleotides as 'activated' donors.[4][5][6][7][8]

Classification by sequence

Sequence-based classification methods have proven to be a powerful way of generating hypotheses for protein function based on sequence alignment to related proteins. The carbohydrate-active enzyme database presents a sequence-based classification of glycosyltransferases into over 90 families.[9] The same three-dimensional fold is expected to occur within each of the families.[10]

Structure

In contrast to the diversity of 3D structures observed for glycoside hydrolases, glycosyltransferase have a much smaller range of structures.[11][12] In fact, according to the Structural Classification of Proteins database, only three different folds have been observed for glycosyltransferases[13] Very recently, a new glycosyltransferase fold was identified for the glycosyltransferases involved in the biosynthesis of the NAG-NAM polymer backbone of peptidoglycan.[14]

Inhibitors

Many inhibitors of glycosyltransferases are known. Some of these are natural products, such as moenomycin, an inhibitor of peptidoglycan glycosyltransferases, the nikkomycins, inhibitors of chitin synthase, and the echinocandins, inhibitors of fungal b-1,3-glucan synthases. Some glycosyltransferase inhibitors are of use as drugs or antibiotics. Moenimycin is used in animal feed as a growth promoter. Caspofungin has been developed from the echinocandins and is in use as an antifungal agent. Ethambutol is an inhibitor of mycobacterial arabinotransferases and is used for the treatment of tuberculosis. Lufenuron is an inhibitor of insect chitin synthases and is used to control fleas in animals.

Determinant of blood type

The ABO blood group system is determined by what type of glucosyltransferases are expressed in the body.

The ABO gene locus expressing the glucosyltransferases has three main alleleic forms: A, B, and O. The A allele encodes 1-3-N-acetylgalactosaminyltransferase that bonds α-N-acetylgalactosamine to D-galactose end of H antigen, producing the A antigen. The B allele encodes 1-3-galactosyltransferase that joins α-D-galactose bonded to D-galactose end of H antigen, creating the B antigen. In case of O allele the exon 6 contains a deletion that results in a loss of enzymatic activity. The O allele differs slightly from the A allele by deletion of a single nucleotide - Guanine at position 261. The deletion causes a frameshift and results in translation of an almost entirely different protein that lacks enzymatic activity. This results in H antigen remaining unchanged in case of O groups.

The combination of glucosyltransferases by both alleles present in each person determines whether there is an AB, A, B or O blood type.

Uses

Glycosyltransferases have been widely used in the both targeted synthesis of specific glycoconjugates as well as the synthesis of differentially glycosylated libraries of drugs, biological probes or natural products in the context of drug discovery and drug development (a process known as glycorandomization).[15] Suitable enzymes can be isolated from natural sources or produced recombinantly. As an alternative, whole cell-based systems utilizing either endogenous glycosyl donors or cell-based systems containing cloned and expressed systems for synthesis of glycosyl donors have been developed. In cell-free approaches, the large-scale application of glycosyltransferases for glycoconjugate synthesis has required access to large quantities of the glycosyl donors. On the flip-side, nucleotide recycling systems that allow the resynthesis of glycosyl donors from the released nucleotide have been developed. The nucleotide recycling approach has a further benefit of reducing the amount of nucleotide formed as a by-product, thereby reducing the amount of inhibition caused to the glycosyltransferase of interest – a commonly observed feature of the nucleotide byproduct.

See also

References

  1. ↑ Williams, GJ; Thorson, JS (2009). "Natural product glycosyltransferases: properties and applications.". Advances in Enzymology and Related Areas of Molecular Biology 76: 55–119. doi:10.1002/9780470392881.ch2. PMID 18990828.
  2. ↑ Etzler ME, Varki A, Cummings RL, Esko JD, Freeze HH, Hart GW, ed. (2008). Essentials of Glycobiology (2nd ed.). Plainview, N.Y: Cold Spring Harbor Laboratory Press. ISBN 0-87969-770-9.
  3. ↑ Schuman B, Evans SV, Fyles TM (August 2013). "Geometric Attributes of Retaining Glycosyltransferase Enzymes Favor an Orthogonal Mechanism". PLoS ONE 8 (8): e71077. doi:10.1371/journal.pone.0071077.
  4. ↑ Zhang, C; Griffith, BR; Fu, Q; Albermann, C; Fu, X; Lee, IK; Li, L; Thorson, JS (1 September 2006). "Exploiting the reversibility of natural product glycosyltransferase-catalyzed reactions.". Science 313 (5791): 1291–4. doi:10.1126/science.1130028. PMID 16946071.
  5. ↑ Zhang, C; Albermann, C; Fu, X; Thorson, JS (27 December 2006). "The in vitro characterization of the iterative avermectin glycosyltransferase AveBI reveals reaction reversibility and sugar nucleotide flexibility.". Journal of the American Chemical Society 128 (51): 16420–1. doi:10.1021/ja065950k. PMID 17177349.
  6. ↑ Zhang, C; Fu, Q; Albermann, C; Li, L; Thorson, JS (5 March 2007). "The in vitro characterization of the erythronolide mycarosyltransferase EryBV and its utility in macrolide diversification.". Chembiochem : A European Journal of Chemical Biology 8 (4): 385–90. doi:10.1002/cbic.200600509. PMID 17262863.
  7. ↑ Zhang, C; Moretti, R; Jiang, J; Thorson, JS (13 October 2008). "The in vitro characterization of polyene glycosyltransferases AmphDI and NysDI.". Chembiochem : A European Journal of Chemical Biology 9 (15): 2506–14. doi:10.1002/cbic.200800349. PMID 18798210.
  8. ↑ Gantt, RW; Peltier-Pain, P; Cournoyer, WJ; Thorson, JS (21 August 2011). "Using simple donors to drive the equilibria of glycosyltransferase-catalyzed reactions.". Nature Chemical Biology 7 (10): 685–91. doi:10.1038/nchembio.638. PMID 21857660.
  9. ↑ CAZypedia Glycosyltransferases
  10. ↑ CAZy Glycosyl Transferase
  11. ↑ Singh, S; Phillips GN, Jr; Thorson, JS (October 2012). "The structural biology of enzymes involved in natural product glycosylation.". Natural Product Reports 29 (10): 1201–37. doi:10.1039/c2np20039b. PMID 22688446.
  12. ↑ Chang, A; Singh, S; Phillips GN, Jr; Thorson, JS (December 2011). "Glycosyltransferase structural biology and its role in the design of catalysts for glycosylation.". Current Opinion in Biotechnology 22 (6): 800–8. doi:10.1016/j.copbio.2011.04.013. PMID 21592771.
  13. ↑ SCOP: Structural Classification of Proteins
  14. ↑ Lovering AL, de Castro LH, Lim D, Strynadka NC (March 2007). "Structural insight into the transglycosylation step of bacterial cell-wall biosynthesis". Science 315 (5817): 1402–5. doi:10.1126/science.1136611. PMID 17347437.
  15. ↑ Gantt, RW; Peltier-Pain, P; Thorson, JS (October 2011). "Enzymatic methods for glyco(diversification/randomization) of drugs and small molecules.". Natural Product Reports 28 (11): 1811–53. doi:10.1039/c1np00045d. PMID 21901218.
This article is issued from Wikipedia - version of the Wednesday, January 27, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.